AbbVie Inc.

(New York Stock Exchange)

Top News rankings and signal summaries are processed using AI and may contain errors.

1
Bullish +75

AbbVie (ABBV) Stock Jumps on Strong Q1 Beat and Upgraded Full-Year Forecast

AI-generated analysis

AbbVie (ABBV) shares rallied in premarket trading after the company reported a strong first-quarter beat, exceeding analyst expectations for both earnings per share and revenue. First-quarter adjusted EPS came in at $2.65 per share against a consensus of $2.59, while total revenue reached $15 billion,...

Bullish Signals

  • Adjusted EPS reached $2.65, surpassing the $2.59 consensus.
  • Revenue hit $15 billion, a strong 12% year-over-year increase.
  • Immunology segment grew 16%, driven by Skyrizi and Rinvoq gains.
  • Neuroscience segment surged 26%, proving successful diversification success.
  • Raised full-year 2026 EPS forecast range to $14.08–$14.28.

Bearish Signals

  • Shares down 13% YTD despite strong earnings.
  • Humira revenue dropped 39% amid biosimilar competition.
  • GAAP net income fell to $695 million.
  • EPS guidance offers little room for error.
  • Stock must recover 13% decline before momentum.
2
Bullish +75

AbbVie Sharpens Immunology Focus With $10.9 Billion Apogee Deal

AI-generated analysis

AbbVie announced on Monday a definitive agreement to acquire Apogee Therapeutics for $10.9 billion, marking the company's largest buyout in over five years. The deal is strategically designed to strengthen AbbVie's immunology portfolio, specifically targeting inflammatory diseases such as atopic dermatitis and asthma, as it...

Bullish Signals

  • AbbVie acquires Apogee for $10.9B, largest buyout in five years.
  • Zumilokibart dosing every 3-6 months beats Dupixent convenience.
  • Immunology franchise generated over $30B revenue in 2025.
  • Analysts view deal as well-received growth asset move.
  • Shares rose 4.6% on positive market sentiment.

Bearish Signals

  • The $10.9 billion acquisition will be funded through debt, increasing AbbVie's leverage and interest obligations.
3
Bullish +65

AbbVie Earnings Call Signals Strong Growth Ahead - TipRanks

Drug approval Earnings report Guidance raised AI-generated analysis

AbbVie reported a strongly positive third quarter with adjusted earnings per share of $3.82, beating guidance by $0.07, and net revenue reaching $17.4 billion, up 10.5% operationally. The company significantly raised its full-year outlook, increasing the adjusted EPS midpoint to $13.95-$13.99 and lifting the revenue...

Bullish Signals

  • Adjusted Q3 earnings hit $3.82, beating guidance midpoint.
  • Net revenue reached $17.4B, up 10.5% operationally.
  • Raised full-year adjusted EPS guidance to $13.95-$13.99.
  • Skyrizi sales rose 22.9% to nearly $5.8 billion.
  • Rinvoq sales climbed 24.3% to $2.7 billion.

Bearish Signals

  • Humira revenue fell 30.6% due to biosimilar competition.
  • Imbruvica sales dropped 26.1%, lowering guidance to $2.1B.
  • Aesthetics revenue declined 1.8% as Juvéderm sales fell 11.8%.
  • Economic uncertainty and lower consumer confidence hurt aesthetics.
  • Vraylar IRA price pressure begins in 2027.
  • FDA issues outstanding on Boey manufacturing matters.
4
Bullish +75

3 Major Reasons for Investors to Buy AbbVie Stock Before July 31st - 24/7 Wall St.

AI-generated analysis

AbbVie (NYSE: ABBV) is positioned ahead of its July 31 Q2 earnings report with strong momentum driven by two blockbuster immunology drugs, Skyrizi and Rinvoq. These products combined generated $6.6 billion in revenue during the first quarter of 2026, effectively replacing Humira as the company's...

Bullish Signals

  • Trades at 18x forward P/E with 0.43 PEG ratio.
  • Raised quarterly dividend 5.5% to $1.73/share.
  • Skyrizi and Rinvoq generated $6.6B Q1 revenue.
  • Raised full-year sales guidance for key drugs.
  • Beta of 0.28 offers low volatility growth.
5
Bullish +75

Inside AbbVie (ABBV) Shares: Immunology, Neuroscience and Botox

AI-generated analysis

AbbVie (ABBV) reported strong financial performance in the second quarter of 2026, with total net revenues reaching $16.99 billion, a 10.2% increase year over year. This growth was driven primarily by its immunology and neuroscience franchises, specifically Skyrizi and Rinvoq, which generated a combined $8.03...

Bullish Signals

  • Revenue grew 10.2% YoY to $16.99B in Q2 2026.
  • Skyrizi and Rinvoq generated $8.03B, exceeding Humira's peak.
  • Adjusted diluted EPS rose 22.9% YoY to $3.65.
  • Raised full-year 2026 guidance by ~$300M to $67.6B.
  • Acquired Apogee Therapeutics for $10.9B to expand immunology.

Bearish Signals

  • Humira revenue fell 36.1% to $756M in Q2 2026 due to biosimilar exclusivity loss.
  • EPS guidance trimmed slightly reflecting dilution from Apogee acquisition transaction.
  • Substantial Allergan debt competes with buybacks for capital allocation.
6
Bullish +72

Cantor Fitzgerald Issues Positive Forecast for AbbVie (NYSE:ABBV) Stock ...

AI-generated analysis

Cantor Fitzgerald has raised its price target for AbbVie (NYSE: ABBV) from $265 to $285, maintaining an overweight rating. This follows a mixed landscape of recent analyst actions, including JPMorgan Chase increasing its target to $280 and DZ Bank upgrading the stock to a strong...

Bullish Signals

  • Cantor Fitzgerald raised price target to $285.
  • AbbVie beat earnings with $3.65 EPS vs $3.61 consensus.
  • Revenue of $16.99B exceeded estimates of $16.80B.
  • Company achieved 10.2% year-over-year revenue increase.
  • Major banks like JPMorgan Chase issued upgrades.

Bearish Signals

  • Negative ROE of -466.39% indicates significant leverage or accounting adjustments.
  • Dividend payout ratio of 195.48% exceeds current quarterly earnings.
7
Bullish +75

27,001 Shares in AbbVie Inc. $ABBV Bought by Arbor Capital Management ...

AI-generated analysis

Arbor Capital Management Inc. ADV established a new position in AbbVie Inc. (NYSE: ABBV) during the first quarter, purchasing 27,001 shares valued at approximately $5.63 million. This acquisition makes AbbVie the firm's largest holding, accounting for roughly 4.6% of its portfolio. Concurrently, several other major...

Bullish Signals

  • Arbor Capital made AbbVie largest holding at 4.6%.
  • Norges Bank acquired $5.87 billion stake in Q4.
  • Wellington Management increased holdings by 457.4% to $2.44B.
  • Capital World Investors lifted position by 106.3% to $2.99B.
  • Institutional ownership stands at 70.23% after accumulation.
  • Q4 earnings of $2.65 beat estimate of $2.59.
  • Revenue reached $15 billion, up 12.4% year-over-year.
  • Analysts forecast full-year earnings of $14.39 per share.
  • Bank of America raised target to $276 with 'buy'.
  • DZ Bank upgraded to 'strong-buy' in late April.
  • Canaccord Genuity lifted target to $273 with 'buy'.
8
Bullish +65

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

AI-generated analysis

AbbVie announced on June 8, 2026, that it will present new clinical data across its blood cancer portfolio at the European Hematology Association (EHA) 2026 Congress in Stockholm. The presentation includes six oral and multiple poster sessions highlighting advancements in multiple myeloma, follicular lymphoma, chronic...

Bullish Signals

  • 96.5% vs 84.8% ORR in low-risk FL-1 subgroup.
  • 30% 24-month PFS vs 13% with epcoritamab monotherapy.
  • No new safety signals observed in EPCORE FL-1.
  • Pipeline includes over 35 investigational medicines.
  • Etentamig shows promise in relapsed/refractory myeloma.

Bearish Signals

  • DLBCL-1 trial showed no significant overall survival improvement for epcoritamab monotherapy.
  • Higher grade 3–4 infections (30% vs 12%) and COVID-19 (36% vs 11%) in epcoritamab arm.
  • Grade 5 adverse events occurred more frequently (17% vs 6%), largely due to severe COVID-19.
  • EPKINLY carries serious risks including CRS, neurologic issues, and potential hospitalization or death.
  • VENCLEXTA poses tumor lysis syndrome risk causing kidney failure requiring strict monitoring.
  • Etentamig and pivekimab sunirine-pvzy are investigational and not approved in the EU.
  • EPKINLY safety warnings include CRS, neurologic problems, and Day 15/22 Cycle 1 hospitalization needs.
9
Bullish +75

AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting

AI-generated analysis

AbbVie reported record financial results at its annual meeting held on May 9, citing total net revenues of $61.2 billion that exceeded initial expectations by over $2 billion. CEO Rob Michael highlighted an all-time high for revenue driven by an 8.6% sales growth, which more...

Bullish Signals

  • Record $61.2B revenue in 2025 beat expectations.
  • Sales grew 8.6% to an all-time high.
  • Adjusted EPS of $10.54 exceeded guidance midpoint.
  • Investment funds ~90 clinical programs for growth.
  • $5B business development focuses on 2030s expansion.
  • Ample capacity to acquire in immunology and oncology.
  • Quarterly dividend rose 5.5% to $1.73/share.
  • Secured tariff protection with $100B investment commitment.
  • Recent approvals include Rinvoq, Emrelis, and Epkinly.

Bearish Signals

  • Annual meeting lacked discussion of potential downsides or risks.
  • $16 billion U.S. Humira revenue erosion pressures growth.
  • Two shareholder governance proposals failed at the annual meeting.
  • 2026 dividend growth will diverge from earnings growth rates.
  • $100 billion decade investment commitment drains near-term cash flow.
  • Earlier-stage pipeline focus introduces timing and success uncertainty.
10
Bullish +75

Price Prediction: Why AbbVie’s Post-Humira Pivot Makes It a Strong Buy

AI-generated analysis

AbbVie (ABBV) recently reported Q1 2026 revenue of $15 billion, surpassing the consensus estimate of $14.72 billion by $280 million and representing a 12.43% year-over-year increase. While GAAP net income fell 45.96% due to significant investment charges of $744 million in intellectual property research and...

Bullish Signals

  • AbbVie revenue beat by $280M to $15B.
  • Skyrizi sales surged 30.9% YoY.
  • Rinvoq growth reached 23.3% to $2.12B.
  • Full-year EPS guidance raised to $14.08-$14.28.
  • Migraine franchise grew: Qulipta +53.6%, Ubrelvy +41.4%.
  • Obesity candidate ABBV-295 showed weight reduction.
  • Elahere achieved >60% response rate in trials.
  • Price target $249.27 with 22 buy ratings.
  • Stock closed up 3.14% on earnings.

Bearish Signals

  • AbbVie missed EPS estimates by $0.02 despite revenue beats.
  • A $744M IPR&D charge reduced earnings per share by $0.41.
  • GAAP net income dropped 45.96% YoY due to significant charges.
  • Humira revenue fell 38.6% and Imbruvica slid 24.7%.
  • FDA issued a Complete Response Letter over manufacturing issues.
  • Growth relies on Skyrizi and Rinvoq avoiding deceleration.
  • Valuation risks include more CR letters or biosimilar competition.
  • U.S. pricing policy shifts could compress margins for key drugs.
  • Phase 2 success of ABBV-295 is a critical growth assumption.
11
Bullish +75

AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results | AbbVie

AI-generated analysis

AbbVie reported its financial results for the fourth quarter and full year 2025, highlighting record net sales achieved in the second full year following the loss of U.S. exclusivity for its key drug, Humira. Robert A. Michael, Chairman and CEO, described 2025 as an outstanding...

Bullish Signals

  • Record net sales despite Humira loss.
  • CEO expects robust growth into 2026.
  • Pipeline advanced with strategic innovation investments.
  • Guidance for 2026 EPS set at $14.37-$14.57.

Bearish Signals

  • 2026 EPS guidance excludes uncertain acquired IPR&D milestones.
  • Growth warnings cite IP challenges and adverse litigation risks.
  • Reconciling non-GAAP metrics distorts reliance on GAAP figures.
  • Net foreign exchange loss exposes earnings to currency drops.
  • No obligation to revise outlook leaves investors exposed.
12
Bullish +75

AbbVie Q1 Earnings Call Highlights

AI-generated analysis

AbbVie Inc. reported first-quarter 2026 results that significantly exceeded analyst expectations, with adjusted earnings per share (EPS) of $2.65 and total net revenues reaching $15.0 billion, representing a 12.4% increase year-over-year. CEO Rob Michael described the performance as exceeding expectations across the diverse portfolio, while...

Bullish Signals

  • AbbVie Q1 adjusted EPS hit $2.65, beating guidance by $0.07.
  • Net revenues reached $15B, surpassing estimates and growing 12.4%.
  • Full-year adjusted EPS guidance raised to $14.08–$14.28.
  • CEO Rob Michael says the company started the year excellently.
  • Immunology segment grew strongly with SKYRIZI sales at $4.5B.
  • SKYRIZI expects global revenues of $21.6B amid demand growth.
  • FDA approved adding genital and scalp psoriasis results to SKYRIZI label.
  • RINVOQ global sales reached $2.1B, up 20.2% operationally.
  • Neuroscience segment revenue rose to nearly $2.9B, up 24.3%.
  • AbbVie raised full-year neuroscience revenue expectations to $12.6B.
  • RINVOQ sales expectations raised to $10.2B globally.
  • Parkinson's therapy VYALEV projected blockbuster sales of $201M.
  • Oncology revenues resilient with VENCLEXTA sales at $770M.
  • AbbVie expects total net revenues of $67.3B for 2026.
  • Aesthetics business posted global sales of nearly $1.2B.

Bearish Signals

  • HUMIRA sales down 40.3% from biosimilar competition.
  • IMBRUVICA revenue down 24.7% due to IRA pricing.
  • JUVÉDERM sales fell 2.9% amid market inflation dynamics.
  • Q1 EPS hit by $0.41 IPR&D expense impact.
  • Guidance omits future IPR&D expense estimates creating uncertainty.
  • Tavapadon approval delayed until late 2026, not immediate.
  • SKYRIZI Crohn's study only met partial endpoints.
13
Bullish +72

AbbVie (NYSE:ABBV) Trading Up 1.4% on Analyst Upgrade

AI-generated analysis

AbbVie Inc. (NYSE: ABBV) shares rose 1.4% to $256.80 following a price target upgrade from Canaccord Genuity, which raised its target from $273.00 to $282.00 while maintaining a buy rating. The stock reached an intraday high of $258.38 with trading volume declining 38% from the...

Bullish Signals

  • Canaccord raised target to $282.00 with buy rating.
  • JPMorgan upgraded to overweight, raising target to $280.00.
  • Piper Sandler set highest target at $298.00.
  • Guggenheim upgraded to buy, raising target to $261.00.
  • DZ Bank upgraded to strong-buy in late April.
  • Citigroup raised target from $230.00 to $260.00.
  • Vanguard added 3 million shares, increasing stake by 1.7%.
  • State Street holdings rose 1.4% to $18.5 billion.
  • Geode Capital boosted position by 10.4% with 4M shares.
  • Bank of America increased stake by 1.4% with 360k shares.
  • AbbVie beat Q1 earnings with $2.65 EPS vs $2.59.

Bearish Signals

  • Dividend payout ratio is 340.89%, exceeding earnings.
14
Bullish +72

Andra AP fonden Acquires 86,969 Shares of AbbVie Inc. $ABBV

AI-generated analysis

Andra AP fonden significantly increased its stake in AbbVie Inc. (NYSE: ABBV) by 44.2% during the first quarter, acquiring an additional 86,969 shares to bring its total holding to 283,811 shares valued at $61.7 million. This investment makes AbbVie the fund's 18th largest position, representing...

Bullish Signals

  • Stake increased 44.2%, adding $61.7 million.
  • Piper Sandler target $298, JPMorgan $280.
  • Revenue $15B beat expectations of $14.72B.
  • Earnings per share $2.65 vs $2.59 estimate.
  • Revenue grew 12.4% year-over-year.
  • Quarterly dividend $1.73 payable August 14.

Bearish Signals

  • Negative return on equity of -576.45% for the quarter.
  • Citigroup and UBS issued neutral ratings despite raising price targets.
  • High PE ratio of 124.81 indicates potential valuation concerns.
15
Bullish +62

Adams Diversified Equity Fund Inc. Sells 58,300 Shares of AbbVie Inc ...

AI-generated analysis

Adams Diversified Equity Fund Inc. reduced its position in AbbVie Inc. by 31.1% in the first quarter, selling 58,300 shares to hold a remaining stake of 129,400 shares valued at $28.1 million. While this major fund decreased its exposure, several smaller institutional investors including Chelsea...

Bullish Signals

  • Revenue hit $15B, up 12.4% year-over-year.
  • EPS reached $2.65, beating estimates by $0.06.
  • Piper Sandler set price target at $298.
  • Canaccord raised target to $273 with buy rating.
  • Guggenheim maintains buy rating at $249 target.
  • Cantor Fitzgerald reiterated overweight rating on shares.
  • Dividend yield stands at 2.8% annually.

Bearish Signals

  • High payout ratio of 340.89% exceeds earnings per share.
  • Negative return on equity of -576.45% for the quarter.
  • Institutional holder reduced position by 31.1% in Q1.
16
Bullish +75

حصلت شركة AbbVie (ABBV) على موافقة ... - albalad.news

AI-generated analysis

في 23 يونيو 2026، أعلنت شركة AbbVie (ABBV) عن موافقات تنظيمية هامة تشمل الموافقة الكندية على عقار Boey لتحسين خطوط الوجه لدى البالغين، وهو أول نوع مصلي E معتمد من التوكسين العصبي البوتولينوم لهذا الغرض. كما وافقت المفوضية الأوروبية على عقار Maviret لعلاج عدوى فيروس...

Bullish Signals

  • AbbVie received Canadian approval for Boey, first botulinum toxin type E.
  • EU approved Maviret as sole treatment for acute and chronic hepatitis C.
  • Canaccord raised AbbVie price target to $273 from $265.
  • AbbVie acquired Apogee Therapeutics for Alzheimer's and asthma assets.
  • AbbVie is one of 12 most profitable S&P 500 stocks.
17
Bullish +72

AbbVie Stock Will Hit $300 on This Date

AI-generated analysis

AbbVie (NYSE: ABBV) is described as an underrated growth story with CEO Robert A. Michael reporting that the company exceeded expectations in Q1 2026. Despite shares trading at $221.59, down 1.43% year-to-date, revenue accelerated by 12.4% year-over-year. Immunology revenue specifically hit $7.29 billion, driven by...

Bullish Signals

  • Q1 2026 revenue accelerated +12.4% year-over-year.
  • Immunology revenue hit $7.29 billion driven by growth.
  • Skyrizi crossed $5.01 billion with >30% growth rate.
  • Neuroscience franchise Qulipta increased performance 53.6%.
  • Stock trades at forward P/E of 17x vs 32% margins.
  • Management raised full-year guidance to $14.08-$14.28.
  • Stock returned 457.85% over 10 years historically.
  • Analysts rate stock bullish with 24 total ratings.

Bearish Signals

  • Net income fell 45.96% due to $744 million R&D charge.
  • Revenue dropped 38.6% as Humira franchise structurally declined.
  • Imbruvica revenue declined 24.7%, pressuring overall top-line growth.
  • Market may treat one-time charges as recurring, depressing multiples.
  • Erosion could derail path to $300 legacy oncology target.
18
Bullish +75

ABBV Stock Up 5% on Robust Q1 Performance: Time to Buy, Sell or Hold?

AI-generated analysis

AbbVie (ABBV) shares gained approximately 5% following the release of robust first-quarter fiscal 2026 results on April 29, which beat analyst estimates for both earnings per share and sales. The company further strengthened investor confidence by raising its full-year guidance for 2026, updating earnings per...

Bullish Signals

  • AbbVie Q1 2026 earnings rose 7.7% while revenues grew 10.3%.
  • Full-year EPS guidance raised to $14.08-$14.28, signaling strong confidence.
  • 2026 revenue guidance increased to $67.3 billion from previous $67 billion.
  • Skyrizi and Rinvoq generated $6.6B Q1 sales with >20% 2026 growth.
  • Rinvoq new indications could add roughly $2B to peak-year sales.
  • Neuroscience portfolio sales surged 24.3% to $2.88 billion driven by Vraylar and Botox.
  • Parkinson's franchise Vyalev holds over $5B in peak sales potential.
  • Robust pipeline includes lutikizumab readouts and regulatory submissions throughout 2026.
  • Management has capacity for M&A deals in immunology, oncology, and neuroscience.

Bearish Signals

  • AbbVie expects low single-digit pricing headwinds for Skyrizi and Rinvoq beyond 2026.
  • Competitive pressure intensified by J&J's Icotyde threatens Skyrizi prescription trends.
  • Humira sales plummeted ~50% in 2025 due to biosimilar erosion.
  • Aesthetics sales projected flat at $5B in 2026 amid macro headwinds.
  • Juvederm sales face further decline due to dermal filler market headwinds.
  • Oncology sales declined 3% to $1.63B Q1 indicating franchise pressure.
19
Bullish +65

AbbVie Options Price In a Sudden 5% Swing—What Investors Must Know Before Oct. 30

Drug approval Earnings report AI-generated analysis

AbbVie (ABBV) is approaching its October 30 earnings report with shares up 28.55% year-to-date, though options pricing suggests a volatile 5% swing in either direction. The stock has historically sold off even after beating estimates, as seen in previous quarters where it fell despite positive...

Bullish Signals

  • Skyrizi revenue grew 24.4% to $5.51 billion.
  • Rinvoq rose 24.5% to $2.53 billion.
  • FDA approved Juvmo for Parkinson's disease.
  • Neuroscience revenue grew 20.3% to $3.23 billion.

Bearish Signals

  • Guidance cut due to $0.14 dilution from Apogee deal.
20
Bullish +65

JPMorgan raises target for AbbVie stock to USD 300

Analyst upgrade AI-generated analysis

JPMorgan raised its price target for AbbVie Inc. (ABBV) to USD 300 on October 8, 2026, marking a significant increase from the previous target of USD 285. This bullish analyst action follows the company's strong second-quarter financial performance, where revenue surged 10.20% year-over-year to reach...

Bullish Signals

  • JPMorgan raised price target to USD 300.
  • Q2 revenue grew 10.20% to USD 16.99B.
  • Adjusted EPS rose to USD 3.65 from USD 2.97.
  • New medicines offset legacy declines, strengthening pipeline.
  • Stock trades near 52-week high at EUR 254.35.

Bearish Signals

  • Humira revenue fell 35.90% to $756M due to patent expiration.
  • Faces $300 price target hurdle after analyst upgrade.